Azmi Nasser, PhD
Supernus Pharmaceuticals, Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Azmi Nasser, PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:45 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03474770 · BIS-001-ER for the Treatment of Adult Focal Impaired Awareness SeizuresSupernus Pharmaceuticals, Inc. · active not recruiting · Focal Impaired Awareness Seizures · study chair
- Ph3NCT02618408 · Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)Supernus Pharmaceuticals, Inc. · completed · Attention Deficit Hyperactivity Disorder (ADHD) · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:45 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:45 UTC. The ranking covers the 200 most relevant of 3 PubMed records, and a shared surname and initials can bring in a namesake. All 3 on PubMed
- Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs.J Rheumatol · 202136 citationsRCR 2.0
- Longer analgesic effect with naproxen sodium than ibuprofen in post-surgical dental pain: a randomized, double-blind, placebo-controlled, single-dose trial.Curr Med Res Opin · 201911 citationsRCR 1.0
- A Pilot Primary Stroke Prevention Program for Elderly Korean Americans.J Neurosci Nurs · 20183 citationsRCR 0.2